Citigroup
RYTM icon

Citigroup’s Rhythm Pharmaceuticals RYTM Stock Holding History

Citigroup’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-150,000
Closed -$3.67M – 5930
2022
Q3 		$3.67M Buy
+150,000
New +$2.79M ﹤0.01% 1726

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Citigroup's RYTM Position: Q2 2026 in Review

Citigroup increased its Rhythm Pharmaceuticals (RYTM) stake by 373% in Q2 2026, buying an estimated $4.16M and bringing the position to 58,347 shares worth $6.48M. The position accounts for ﹤0.01% of the portfolio, ranked #1927.

Citigroup first reported a position in RYTM in Q4 2017 and has held it in 35 quarters since. The position peaked at $8.26M in Q1 2024. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Citigroup held 58,347 shares of Rhythm Pharmaceuticals worth $6.48M as of Q2 2026.
  • Citigroup bought 46,011 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $4.16M.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #1927 holding.
  • Citigroup first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 35 quarters since.
  • Citigroup's Rhythm Pharmaceuticals position peaked at $8.26M in Q1 2024.
  • 304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.